Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren's syndrome with rituximab

Journal of Clinical Rheumatology

Volumn 17, Issue 8, 2011, Pages 454-

  Swartz, Morris A ^a   Vivino, Frederick B ^a,b  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FUNCTION; LUNG INFILTRATE; LUNG NODULE; LYMPHOCYTIC INTERSTITIAL PNEUMONIA; NOTE; PRIORITY JOURNAL; RECURRENCE RISK; SJOEGREN SYNDROME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; SJOGREN'S SYNDROME; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 82455212733     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31823ac199     Document Type: Note

References (4)

1. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960-968.
2. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue and Sjogren's syndrome with rituximab: Results are randomized double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541-1544.
3. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310-317.
4. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis. 2007;66:351-357.